Eris Lifesciences Q1 मध्ये २१% नफा वाढून ₹१४२ कोटींवर, पण मार्जिनवर दबाव
NiveshIQ
NSE: ERIS · Healthcare
Eris Lifesciences Ltd.
₹1,426.50▲ ₹35.70 (+2.57%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ERIS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Eris Lifesciences Ltd.
Eris Lifesciences Limited is a leading Indian pharmaceutical company specializing in domestic branded formulations for chronic and sub-chronic therapies. The company offers a diverse portfolio of branded formulations across various therapeutic areas, including anti-diabetes, cardiovascular, and dermatology. In Q1 FY27, Eris Lifesciences reported a 14.5% growth in Profit After Tax (PAT) driven by strong domestic formulations growth, particularly in insulin and GLP-1 businesses. The company has achieved a top-5 market position in anti-diabetes therapy, underscoring its competitive position in the Indian market. Eris Lifesciences generates revenue primarily through wholesale drug distributors, stockists, retail, and e-commerce pharmacies, with a revenue breakdown of ₹3115 Cr. The company's re
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,009 Cr +143.20% | ₹2,893 Cr +44.00% | ₹3,129 Cr +8.10% |
| EBITDA Margin | 33.60% | 35.15% | 30.85% |
| Net Profit | ₹397.00 Cr +146.60% | ₹375.00 Cr -5.50% | ₹501.00 Cr +33.60% |
| EPS | ₹28.82 | ₹25.89 | ₹24.80 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Eris Lifesciences Q1 PAT rises 14.5% on strong domestic formulations growth; insulin, GLP-1 businesses...
Eris Lifesciences posts 14.5% growth in Q1 PAT for FY27
🔒
+ 3 more stories about Eris Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹873 Cr, PAT ₹143 Cr, EPS ₹10.28, EBITDA margin 34.2%. Growth context: revenue QoQ +15.4%, PAT QoQ +7.8%. Street verdict: inline, revenue surprise +1.9%, PAT surprise -4.0%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement as the primary near-term g...
FY26 (last completed FY): revenue ₹3, 129 Cr, PAT ₹501 Cr, EBITDA margin 30.9%, EPS ₹24.80. Year-on-year: revenue YoY +8...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ERIS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ERIS alongside your other holdings
Unlock full ERIS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Eris Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Eris Lifesciences Ltd. (ERIS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Eris Lifesciences Ltd.?
Eris Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,934,335.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.